Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 8/20 | 0.78 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.62 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.62 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.62 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.62 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.62 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.62 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.62 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | RORA | P35398 | 1/20 | 0.49 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | SRD5A1 | P18405 | 7/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13630375 | 1.00 | CDC25A (0.78) | CDC25AGABRA1GABRB1GABRG2GABRB3 | |
| SCHEMBL3134072 | 1.00 | CDC25A (0.78) | CDC25AGABRA1GABRB1GABRG2GABRB3 | |
| SCHEMBL13521601 | 1.00 | CDC25A (0.78) | CDC25AGABRA1GABRB1GABRG2GABRB3 | |
| SCHEMBL3138543 | 0.80 | NPC1L1 (0.61) | CDC25AGABRA1GABRB1GABRG2GABRB3 | |
| SCHEMBL3138537 | 0.80 | NPC1L1 (0.61) | CDC25AGABRA1GABRB1GABRG2GABRB3 | |
| SCHEMBL30650227 | 0.80 | NPC1L1 (0.61) | CDC25AGABRA1GABRB1GABRG2GABRB3 | |
| SCHEMBL13521611 | 0.80 | NPC1L1 (0.61) | CDC25AGABRA1GABRB1GABRG2GABRB3 | |
| SCHEMBL13629834 | 0.79 | CDC25A (0.57) | CDC25AGABRA1GABRB1GABRG2GABRB3 | |
| SCHEMBL13521632 | 0.79 | CDC25A (0.57) | CDC25AGABRA1GABRB1GABRG2GABRB3 | |
| SCHEMBL24425755 | 0.77 | GABRA1 (1.00) | CDC25AGABRA1GABRB1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100003711-A1 | Methods to identify therapeutic agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090275064-A1 | Methods to identify therapeutic agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-11-05 | — | — | US | disclosed |
| US-20070059242-A1 | METHODS TO IDENTIFY THERAPEUTIC AGENTS | SCRIPPS RESEARCH INSTITUTE, THE | 2007-03-15 | — | — | US | disclosed |
| US-20060217359-A1 | Therapeutic procedures | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-28 | — | — | US | disclosed |
| US-20060210554-A1 | Detection of cholesterol ozonation products | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-09-21 | — | — | US | disclosed |
| EP-1670812-A2 | OZONATION PRODUCTS OF CHOLESTEROL FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS AND/OR CARDIOVASCULAR DISEASES | The Scripps Research Institute (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1668026-A1 | DETECTION OF CHOLESTEROL OZONATION PRODUCTS | The Scripps Research Institute (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050085557-A1 | Oxidation of cholesterol in atherosclerosis plaque; cytotoxic | SCRIPPS RESEARCH INSTITUTE, THE | 2005-04-21 | — | — | US | disclosed |
| US-20050085556-A1 | Detection of cholesterol ozonation products | SCRIPPS RESEARCH INSTITUTE, THE | 2005-04-21 | — | — | US | disclosed |
| WO-2005023830-A2 | OZONATION PRODUCTS OF CHOLESTEROL FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS AND/OR CARDIOVASCULAR DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023831-A1 | DETECTION OF CHOLESTEROL OZONATION PRODUCTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070059242-A1 | METHODS TO IDENTIFY THERAPEUTIC AGENTS | MSR1, SCARB1, LDLR | CDC25A 3977/4885GABRA1 2179/4885GABRB1 2882/4885 |
| US-20050085556-A1 | Detection of cholesterol ozonation products | APOB, CETP, PCSK9 | CDC25A 4303/4885GABRA1 4736/4885GABRB1 4851/4885 |
| US-20050085557-A1 | Oxidation of cholesterol in atherosclerosis plaque; cytotoxic | APOB, LDLR, CETP | CDC25A 4259/4885GABRA1 3677/4885GABRB1 3828/4885 |
| US-20060217359-A1 | Therapeutic procedures | APOB, LIPA, CETP | CDC25A 4132/4885GABRA1 3922/4885GABRB1 3923/4885 |
| US-20090275064-A1 | Methods to identify therapeutic agents | MSR1, SCARB1, LDLR | CDC25A 3921/4885GABRA1 2267/4885GABRB1 2878/4885 |
| US-20060210554-A1 | Detection of cholesterol ozonation products | APOB, CETP, PCSK9 | CDC25A 4303/4885GABRA1 4736/4885GABRB1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.